EVOQ.BO · BSE
Evoq Remedies Limited
₹1.79
+4.68% (+₹0.08)
Prev. close
₹1.71
Volume
24,000
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range — no analyst has covered this yet.
Explore by date range →Analyst opinions
Fundamentals
About Evoq Remedies Limited
Evoq Remedies Limited engages in the pharmaceutical business in India. The company trades in and acts as a commission agent for pharmaceutical products. It also manufactures, distributes, and exports commercial grade, refined, pale pressed grade, and first pressed degummed castor oils; castor oil and de oil cakes; and high protein castor meals. Evoq Remedies Limited was incorporated in 2010 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Bhumishth Narendrabhai Patel
Headquarters
Ahmedabad
Website
evoqremedies.comExchange
View on BSE ↗Key stats
Market cap
₹3.83 Cr
Dividend yield
0.00%
EPS (TTM)
₹-0.10
Beta (1Y · daily vs NIFTY 50)
0.99
Beta (5Y · monthly vs NIFTY 50)
2.23
Shares float
1.52 Cr
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
Left off as not meaningful (growth from a very small base, beyond ±400%): Fixed assets FY25 (+1494%).
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹16.78 Cr | ₹20.39 Cr | ₹4.05 Cr | ₹11.76 Cr | ₹25.51 Cr | |
EBITDA | — | ₹-3.73 Cr | ₹-1.58 Cr | ₹17.71 L | ₹-19.99 L |
| ₹1.09 Cr | ₹1.62 Cr | ₹45.24 L | ₹8.82 L | ₹-23.99 L | |
Diluted EPS | ₹0.7 | ₹1.19 | ₹0.33 | ₹0.06 | — |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹34.90 Cr | ₹36.86 Cr | ₹50.01 Cr | ₹51.94 Cr | |
| — | ₹9.58 Cr | ₹4.24 Cr | ₹0 | ₹7.30 L | |
Stockholders' equity | — | ₹24.79 Cr | ₹25.24 Cr | ₹44.54 Cr | ₹44.30 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-4.35 Cr | ₹5.32 Cr | ₹-14.62 Cr | ₹-28.19 L | |
Investing cash flow | — | ₹-1.31 L | ₹-1.20 L | ₹-25.81 L | ₹0 |
| — | ₹1.42 Cr | ₹-5.34 Cr | ₹14.97 Cr | ₹7.30 L | |
Capital expenditure | — | ₹-1.31 L | ₹-1.20 L | ₹-25.81 L | — |
End cash position | — | ₹15.36 L | ₹12.34 L | ₹21.41 L | ₹52,000 |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Evoq Remedies Limited | ₹4.08 Cr | ₹1.63 | — | 0.09 | -0.5% | 0.00 | +117.0% | -66.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.